Literature DB >> 9843067

Frequency of relapses in patients with polymyositis and dermatomyositis.

B A Phillips1, P Zilko, M J Garlepp, F L Mastaglia.   

Abstract

The frequency of clinical and biochemical relapses was determined in a group of 50 patients with polymyositis (PM), dermatomyositis (DM), or overlap syndromes who were followed for periods of up to 13 years. Relapses occurred in 30 of the 50 patients (60%) during the period of follow-up. The annual relapse rate was not significantly different in the three groups of patients. Subclinical relapses occurred in each group but were less frequent in the DM than in the PM and overlap groups. Relapses could occur at any time but were more frequent during periods of stable maintenance therapy. There was no correlation between relapses and initial disease severity, delay to diagnosis and commencement of treatment, or any class I or II histocompatibility locus antigen.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9843067     DOI: 10.1002/(sici)1097-4598(199812)21:12<1668::aid-mus7>3.0.co;2-#

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  6 in total

Review 1.  [Current treatments of dermatomyositis and polymyositis].

Authors:  J Richter; C Iking-Konert
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

2.  Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy.

Authors:  G J D Hengstman; H J ter Laak; W T M Vree Egberts; I E Lundberg; H M Moutsopoulos; J Vencovsky; A Doria; M Mosca; W J van Venrooij; B G M van Engelen
Journal:  Ann Rheum Dis       Date:  2006-05-05       Impact factor: 19.103

3.  Characterization of relapses in adult idiopathic inflammatory myopathies.

Authors:  Sandeep K Agarwal; Paul A Monach; William P Docken; Jonathan S Coblyn
Journal:  Clin Rheumatol       Date:  2005-11-03       Impact factor: 2.980

4.  Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand.

Authors:  Naruemon Bamrungsawad; Nathorn Chaiyakunapruk; Nilawan Upakdee; Chayanin Pratoomsoot; Rosarin Sruamsiri; Piyameth Dilokthornsakul
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

5.  The long-term outcome of anti-Jo-1-positive inflammatory myopathies.

Authors:  Michael Späth; Mira Schröder; Beate Schlotter-Weigel; Maggie C Walter; Hubert Hautmann; Gerda Leinsinger; Dieter Pongratz; Wolfgang Müller-Felber
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

6.  Subclinical systolic and diastolic myocardial dysfunction in polyphasic polymyositis/dermatomyositis: a 2-year longitudinal study.

Authors:  Andrea Péter; Ágnes Balogh; Zoltán Csanádi; Katalin Dankó; Zoltan Griger
Journal:  Arthritis Res Ther       Date:  2022-09-10       Impact factor: 5.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.